Several studies have explored the addition of metformin to progestin therapy, motivated by its anti-proliferative and insulin-sensitizing effects, particularly in patients with metabolic comorbidities such as PCOS or obesity. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.